Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2023 |
| Outros Autores: | , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10362/158496 |
Resumo: | Funding Information: GM reports support for advisory board/consultation positions for AstraZeneca , Roche , Novartis , Lilly and Pfizer . AP reports honoraria and/or advisory fees from: AstraZeneca , Bristol Myers Squibb (BMS), Roche /Italfarma. MS reports honoraria and/or advisory fees from: Amgen , AstraZeneca , BMS, Boehringer Ingelheim , Janssen, Lilly , Novartis , Pfizer , Roche , Sanofi Avemtis, Siemens Healthineers , Takeda . He also declares research support (institutional) from: Amgen , BMS, Dracen Pharmaceuticals , Janssen, Novartis , Pfizer , Siemens Healthineers. AA took part in advisory boards for Amgen , AstraZeneca , Bayer , Daiichi, EISAI, Genomic Health , Hengrui, Innate, Ipsen , Leo Pharma, Lilly , Merck , Merck Sharp & Dohme (MSD), Novartis , Pfizer , Seattle Genetics . He received speaker fees from Amgen , AstraZeneca , Bayer , Daiichi, Eisai , Genomic Health , Ipsen , Leo Pharma, Lilly , Merck , MSD, Novartis , Pfizer , Seattle Genetics . He received research grants from BMS, Roche . All other authors have declared no conflicts of interests. Publisher Copyright: © 2022 The Authors |
| id |
RCAP_b4703b79d16e19dc0d475fc31226d64b |
|---|---|
| oai_identifier_str |
oai:run.unl.pt:10362/158496 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancera survey of oncologist perceptionsclinical challengesimmune checkpoint inhibitorsimmunotherapyNSCLCOncologyCancer ResearchSDG 3 - Good Health and Well-beingFunding Information: GM reports support for advisory board/consultation positions for AstraZeneca , Roche , Novartis , Lilly and Pfizer . AP reports honoraria and/or advisory fees from: AstraZeneca , Bristol Myers Squibb (BMS), Roche /Italfarma. MS reports honoraria and/or advisory fees from: Amgen , AstraZeneca , BMS, Boehringer Ingelheim , Janssen, Lilly , Novartis , Pfizer , Roche , Sanofi Avemtis, Siemens Healthineers , Takeda . He also declares research support (institutional) from: Amgen , BMS, Dracen Pharmaceuticals , Janssen, Novartis , Pfizer , Siemens Healthineers. AA took part in advisory boards for Amgen , AstraZeneca , Bayer , Daiichi, EISAI, Genomic Health , Hengrui, Innate, Ipsen , Leo Pharma, Lilly , Merck , Merck Sharp & Dohme (MSD), Novartis , Pfizer , Seattle Genetics . He received speaker fees from Amgen , AstraZeneca , Bayer , Daiichi, Eisai , Genomic Health , Ipsen , Leo Pharma, Lilly , Merck , MSD, Novartis , Pfizer , Seattle Genetics . He received research grants from BMS, Roche . All other authors have declared no conflicts of interests. Publisher Copyright: © 2022 The AuthorsBackground: Immune checkpoint-inhibitors (ICIs) are changing outcomes in different cancer settings, notably for patients with non-small-cell lung cancer (NSCLC). There are, however, still important gaps of evidence for clinical practice when using these novel treatments. In this study, we assessed physicians’ opinion and experience on challenges for clinical practice with ICIs monotherapy in NSCLC. Methods: A survey was conducted on experienced physicians treating patients with NSCLC with ICIs. Two rounds of pilot tests were carried out for validation among a group of experts. Topics under analysis were in relation to treatment of elderly populations, performance status, brain metastases, use of steroids or antibiotics, the effects of gut microbiome, autoimmune diseases, human immunodeficiency virus infection, solid organ transplants, use of anti-programmed cell death protein 1 versus anti-programmed death-ligand 1 drugs, atypical tumour responses, predictors of response, duration of treatment and a final open question on additional relevant challenges. Results: Two hundred and twenty-one answers were collected, including 106 (48%) valid answers from experts for final analysis (physicians who have treated at least 20 patients with NSCLC with ICIs). The vast majority agreed that the selected topics in this study are important challenges ahead and more evidence is needed. Moreover, predictors of response, treating brain metastasis, shorter duration of treatment, the effects of gut microbiome and concomitant use of steroids were voted the most important topics to be further addressed in prospective clinical research. Conclusions: This survey contributed to understanding which are the main challenges for clinical practice with ICIs monotherapy in NSCLC. It can also contribute to guide further clinical research, considering the opinions and experience of those who regularly treat NSCLC patients with ICIs.Escola Nacional de Saúde Pública (ENSP)Comprehensive Health Research Centre (CHRC) - pólo NMSNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNCastelo-Branco, L.Morgan, G.Prelaj, A.Scheffler, M.Canhão, H.Van Meerbeeck, J. P.Awada, A.2023-09-29T22:22:58Z2023-022023-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/158496eng2059-7029PURE: 72795931https://doi.org/10.1016/j.esmoop.2022.100764info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:40:55Zoai:run.unl.pt:10362/158496Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:57:10.632624Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer a survey of oncologist perceptions |
| title |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer |
| spellingShingle |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer Castelo-Branco, L. clinical challenges immune checkpoint inhibitors immunotherapy NSCLC Oncology Cancer Research SDG 3 - Good Health and Well-being |
| title_short |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer |
| title_full |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer |
| title_fullStr |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer |
| title_full_unstemmed |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer |
| title_sort |
Challenges and knowledge gaps with immune checkpoint inhibitors monotherapy in the management of patients with non-small-cell lung cancer |
| author |
Castelo-Branco, L. |
| author_facet |
Castelo-Branco, L. Morgan, G. Prelaj, A. Scheffler, M. Canhão, H. Van Meerbeeck, J. P. Awada, A. |
| author_role |
author |
| author2 |
Morgan, G. Prelaj, A. Scheffler, M. Canhão, H. Van Meerbeeck, J. P. Awada, A. |
| author2_role |
author author author author author author |
| dc.contributor.none.fl_str_mv |
Escola Nacional de Saúde Pública (ENSP) Comprehensive Health Research Centre (CHRC) - pólo NMS NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
| dc.contributor.author.fl_str_mv |
Castelo-Branco, L. Morgan, G. Prelaj, A. Scheffler, M. Canhão, H. Van Meerbeeck, J. P. Awada, A. |
| dc.subject.por.fl_str_mv |
clinical challenges immune checkpoint inhibitors immunotherapy NSCLC Oncology Cancer Research SDG 3 - Good Health and Well-being |
| topic |
clinical challenges immune checkpoint inhibitors immunotherapy NSCLC Oncology Cancer Research SDG 3 - Good Health and Well-being |
| description |
Funding Information: GM reports support for advisory board/consultation positions for AstraZeneca , Roche , Novartis , Lilly and Pfizer . AP reports honoraria and/or advisory fees from: AstraZeneca , Bristol Myers Squibb (BMS), Roche /Italfarma. MS reports honoraria and/or advisory fees from: Amgen , AstraZeneca , BMS, Boehringer Ingelheim , Janssen, Lilly , Novartis , Pfizer , Roche , Sanofi Avemtis, Siemens Healthineers , Takeda . He also declares research support (institutional) from: Amgen , BMS, Dracen Pharmaceuticals , Janssen, Novartis , Pfizer , Siemens Healthineers. AA took part in advisory boards for Amgen , AstraZeneca , Bayer , Daiichi, EISAI, Genomic Health , Hengrui, Innate, Ipsen , Leo Pharma, Lilly , Merck , Merck Sharp & Dohme (MSD), Novartis , Pfizer , Seattle Genetics . He received speaker fees from Amgen , AstraZeneca , Bayer , Daiichi, Eisai , Genomic Health , Ipsen , Leo Pharma, Lilly , Merck , MSD, Novartis , Pfizer , Seattle Genetics . He received research grants from BMS, Roche . All other authors have declared no conflicts of interests. Publisher Copyright: © 2022 The Authors |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023-09-29T22:22:58Z 2023-02 2023-02-01T00:00:00Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/158496 |
| url |
http://hdl.handle.net/10362/158496 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
2059-7029 PURE: 72795931 https://doi.org/10.1016/j.esmoop.2022.100764 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799138155117412352 |